Dermatology World March 2011 : Page 15

In the treatment of actinic keratosis What will your patients pay for significant lesion reduction? $ The Zyclara Zero Program Zyclara Patient Savings Card RxBIN: 610524 RxPCN: Loyalty RxGRP: 50775525 ISSUER: (80840) Most card holders pay $0 per prescription • Maximum benefit of $300 per use • Limit of 2 uses per card; some restrictions apply* ID: 01234567 • 36% of patients had complete clearance vs 6% for placebo ( P <.001) 1 • 59% had partial clearance vs 23% for placebo ( P <.001) 1 Zyclara Cream is indicated for the topical treatment of clinically typical visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults. In clinical studies, the most common side effects involved skin reactions in the application area. These reactions included erythema, scabbing or crusting, flaking, scaling or dryness, edema, erosion or ulceration, and weeping or exudate. Most skin reactions were rated as mild to moderate. Intense local inflammatory reactions and/or flu-like systemic signs and symptoms can occur. Dosing interruptions may be required. Exposure to natural or artificial sunlight (tanning beds or UVA/B treatment) should be avoided or minimized during use of Zyclara Cream. Please see Brief Summary of Full Prescribing Information on adjacent page. Visit us at *Patient not eligible if any one of the following apply: (1) prescriptions are paid in part or full by any state or federally funded programs including but not limited to Medicare or Medicaid, Medigap, VA, DOD, or TriCare; (2) patient does not have any prescription drug benefits; (3) patient is a resident of MA; (4) where prohibited by law; (5) patient is under the age of 18. LoyaltyScript ® is not an insurance card. For questions regarding setup, claim transmission, patient eligibility, or other issues, call the ZYCLARA Patient Savings Card Program at 1-877-264-2440 (8:00 am through 8:00 pm EST, Monday through Friday). Reference: 1. Swanson N, Abramovits W, Berman B, et al. Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of 2 placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. J Am Acad Dermatol. 2010;62(4):582-590. ©2011 Graceway Pharmaceuticals, LLC, Bristol, TN ZYC0910179a

Graceway Pharmaceuticals

Using a screen reader? Click Here